Briefing
Circulating tumor DNA monitoring in ovarian cancer patients receiving PARPi maintenance therapy: Can we further personalize treatment?
ctDNA monitoring during PARP-inhibitor maintenance in ovarian cancer, discussing whether it can further personalize treatment.
- Design: Evidence level 3
- Assay: Not named in the abstract